Sanara MedTech Inc. — Director's Dealing 2025

Feb 27, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Sanara MedTech Inc. (SMTI)
CIK: 0000714256
Period of Report: 2025-02-25

Reporting Person: Nixon Ronald T (Director, Chief Executive Officer, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-25	Common Stock	A	7534	—	Acquired	64042	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2452731	Indirect
Common Stock	963856	Indirect

Footnotes

F1: Represents shares of restricted stock granted to the reporting person pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan. The restricted stock will vest in three equal installments, with one-third of the shares vesting on February 25, 2026, 2027 and 2028, respectively.

F2: Represents shares of the Company's common stock owned of record by CGI Cellerate RX, LLC, which is a wholly owned subsidiary of Catalyst Rochal, LLC. Mr. Nixon is a manager of Catalyst Rochal, LLC. By virtue of these relationships, Mr. Nixon, Catalyst Rochal, LLC and CGI Cellerate RX, LLC may be deemed to share voting and dispositive control over the common stock. Mr. Nixon and Catalyst Rochal, LLC disclaim beneficial ownership of any common stock held or beneficially owned by CGI Cellerate RX, LLC, except to the extent of each of their pecuniary interests therein.

F3: Represents shares of the Company's common stock owned of record by FA Sanara, LLC ("FA Sanara"). FA Sanara is managed by Family Alignment, LLC ("Family"), which is managed by Catalyst Group, Inc. ("Catalyst"). Mr. Nixon is a controlling shareholder and President of Catalyst. Mr. Nixon, Catalyst, Family and FA Sanara may be deemed to share voting and dispositive control over the common stock. Mr. Nixon, Catalyst and Family disclaim beneficial ownership of any common stock held or beneficially owned by FA Sanara, except to the extent of each of their pecuniary interests therein.